FMS

Business Context and Reporting Period

Company: Fresenius Medical Care AG & Co. KGaA
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three months ended March 31, 2022
Business Overview: The Company is the world's leading provider of products and services for individuals with renal diseases, operating a vertically integrated business model comprising health care services (dialysis clinics) and health care products (machines, disposables, pharmaceuticals). Operations are reported across four geographic segments: North America, EMEA, Asia-Pacific, and Latin America.

Key Financial Metrics

Note: Free Cash Flow is defined as net cash provided by operating activities after capital expenditures, before acquisitions and investments.

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenue increased 8% (3% at constant currency). Growth was driven by favorable foreign currency translation (+5%) and a partial reversal of an accrual related to a revenue recognition adjustment for accounts receivable in legal dispute (+1%).
• Profitability Decline: Operating income decreased 27% (30% at constant currency). This was primarily driven by a 22% increase in Selling, General, and Administrative (SG&A) expenses, which rose to €870 million from €712 million.
• SG&A Drivers: Increased costs were attributed to foreign currency translation impacts, costs associated with the FME25 transformation program, impacts related to the war in Ukraine, higher personnel expenses, and unfavorable investment revaluations.
• Segment Performance:
  • North America: Revenue up 9%; Operating income down 24% due to higher personnel costs, inflation, and COVID-19 related excess mortality.
  • EMEA: Revenue flat; Operating income down 23% primarily due to impacts from the war in Ukraine.
  • Asia-Pacific: Revenue up 8%; Operating income up 16% driven by a gain from the sale of clinics and product growth.
  • Latin America: Revenue up 15%; Operating income up 68% driven by favorable currency effects.
• Cash Flow: Net cash from operating activities decreased to €159 million, largely due to the recoupment of €170 million in advanced payments received in 2020 under the Medicare Accelerated and Advance Payment Program.

Guidance, Outlook, Risks, and Unusual Items

• Strategic Transformation (FME25): The Company is executing the FME25 program to transform its operating model into two global segments (Health Care Products and Health Care Services) by 2023 to strengthen profitability.
• War in Ukraine: The conflict has introduced significant risks, including inflationary pressure on energy and raw materials, potential supply chain disruptions, and currency devaluation. While direct asset exposure is less than 1% of total assets, the Company has accrued costs related to bad debt and inventory allowances in the region.
• Reimbursement Environment: Approximately 33% of consolidated revenue is from U.S. federal programs. The suspension of U.S. Sequestration (Medicare spending cuts) ended March 31, 2022, with a 1% reduction effective April 1, 2022, and a full 2% resumption expected July 1, 2022.
• Value-Based Care: On March 21, 2022, the Company announced an agreement to combine Fresenius Health Partners with InterWell Health and Cricket Health to create a new entity targeting 270,000 patients by 2025. Closing is subject to regulatory review.
• Legal and Regulatory: The Company is subject to ongoing investigations and litigation, including a non-prosecution agreement with the DOJ/SEC regarding FCPA violations (monitorship expected to conclude in 2022) and various False Claims Act investigations. A temporary pause on shipping new dialysis machines in the U.S. was recommended by the FDA in April 2022, though the Company does not expect a material financial impact.

Investor Verification Checklist

• Reimbursement Impact: Verify the financial impact of the resumption of U.S. Sequestration cuts (1% in Q2, 2% in Q3) on North America margins.
• Ukraine Exposure: Monitor updates on bad debt provisions, inventory write-downs, and operational continuity in Russia and Ukraine.
• FME25 Execution: Track progress on cost savings and the timeline for the reorganization into two global segments.
• Merger Closing: Confirm regulatory approval and closing date for the Fresenius Health Partners/InterWell/Cricket Health combination.
• Working Capital: Assess the normalization of Days Sales Outstanding (DSO), which increased to 69 days in Q1 2022 from 62 days in Q4 2021, partly due to Medicare payment recoupments.